[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alumis Inc (ALMS)

Alumis Inc (ALMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,429,997
  • Shares Outstanding, K 127,492
  • Annual Sales, $ 24,050 K
  • Annual Income, $ -243,330 K
  • EBIT $ -451 M
  • EBITDA $ -447 M
  • 60-Month Beta -0.56
  • Price/Sales 108.09
  • Price/Cash Flow N/A
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 95.33% (-18.16%)
  • Historical Volatility 58.93%
  • IV Percentile 14%
  • IV Rank 2.85%
  • IV High 1,143.00% on 11/12/25
  • IV Low 64.56% on 08/27/25
  • Expected Move (DTE 12) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.80
  • Today's Volume 56
  • Volume Avg (30-Day) 269
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 13,261
  • Open Int (30-Day) 11,790
  • Expected Range 19.06 to 19.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 5
  • High Estimate $-0.55
  • Low Estimate $-0.83
  • Prior Year $-1.17
  • Growth Rate Est. (year over year) +40.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.03 +0.13%
on 06/05/26
26.50 -28.08%
on 05/06/26
-7.07 (-27.06%)
since 05/05/26
3-Month
19.03 +0.13%
on 06/05/26
28.44 -32.98%
on 03/10/26
-8.58 (-31.04%)
since 03/05/26
52-Week
2.76 +590.55%
on 06/24/25
30.60 -37.71%
on 02/19/26
+15.71 (+468.96%)
since 06/05/25

Most Recent Stories

More News
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late - breaking oral presentation of Phase 3 envudeucitinib data in moderate - to - severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early...

ALMS : 19.06 (-6.52%)
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements...

ALMS : 19.06 (-6.52%)
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis...

ALMS : 19.06 (-6.52%)
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity...

ALMS : 19.06 (-6.52%)
Alumis to Present at the Leerink Partners Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 19.06 (-6.52%)
Alumis to Participate in Upcoming February Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 19.06 (-6.52%)
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 19.06 (-6.52%)
Alumis Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 19.06 (-6.52%)
Should You Chase the Rally in Alumis Stock Today?

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

JNJ : 232.77 (+2.02%)
ALMS : 19.06 (-6.52%)
BMY : 57.27 (+1.18%)
Alumis Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 19.06 (-6.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN...

See More

Key Turning Points

3rd Resistance Point 22.33
2nd Resistance Point 21.66
1st Resistance Point 20.36
Last Price 19.06
1st Support Level 18.40
2nd Support Level 17.73
3rd Support Level 16.43

See More

52-Week High 30.60
Fibonacci 61.8% 19.97
Last Price 19.06
Fibonacci 50% 16.68
Fibonacci 38.2% 13.39
52-Week Low 2.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.